With LB Pharmaceuticals, Turner “liked the fact that it’s a very focused neuropsych company; this is where we’re going. And I also liked the fact that there was a near-term catalyst with our Phase 2 clinical program.” In other words, the company had a clear strategy in place; all it needed was a leader who could execute effectively.